CSX Corporation (CSX) Stock Forecast
Data as of Oct 31, 2026Industrials · Current price $51.94 (-0.58%)
Price Target Range
Consensus Price Target Over Time
Analyst Rating Distribution
Last 3 Months
6-Month Trend
Latest Analyst Forecasts
Price targets issued by Wall Street analysts. Upside calculated against today's price.
| Date | Analyst | Firm | Price Target | Upside |
|---|---|---|---|---|
| Jan 23, 2026 | David Vernon | Bernstein | $36.00 | -30.7% |
| Dec 18, 2025 | Walter Spracklin | RBC Capital | $40.00 | -23.0% |
| Oct 17, 2025 | Stephanie Moore | Jefferies | $42.00 | -19.1% |
| Oct 17, 2025 | Q3 EPS | Evercore ISI | $39.00 | -24.9% |
| Oct 17, 2025 | Thomas Wadewitz | UBS | $45.00 | -13.4% |
| Sep 25, 2025 | Christian Wetherbee | Wells Fargo | $40.00 | -23.0% |
| Jul 25, 2025 | Daniel Moore | Robert W. Baird | $44.00 | -15.3% |
| Mar 27, 2025 | Bascome Majors | Susquehanna | $37.00 | -28.8% |
| Feb 3, 2025 | Rick Paterson | Loop Capital Markets | $34.00 | -34.5% |
| Oct 17, 2024 | Walter Spracklin | RBC Capital | $35.00 | -32.6% |
| Oct 17, 2024 | Christian Wetherbee | Wells Fargo | $34.00 | -34.5% |
| Oct 17, 2024 | Stephanie Moore | Jefferies | $37.00 | -28.8% |
| Oct 17, 2024 | Fadi Chamoun | BMO Capital | $39.00 | -24.9% |
| Oct 17, 2024 | Jonathan Chappell | Evercore ISI | $37.00 | -28.8% |
| Oct 17, 2024 | Ariel Rosa | Citigroup | $41.00 | -21.1% |
| Oct 2, 2024 | Bascome Majors | Susquehanna | $42.00 | -19.1% |
| Sep 25, 2024 | Brandon Oglenski | Barclays | $40.00 | -23.0% |
| Aug 23, 2024 | Scott Group | Wolfe Research | $38.00 | -26.8% |
| Jul 8, 2024 | Daniel Imbro | Stephens | $42.00 | -19.1% |
| Apr 18, 2024 | Jordan Alliger | Goldman Sachs | $44.00 | -15.3% |
Top Analysts Covering CSX
CSX vs Sector & Market
| Metric | CSX | Industrials Avg | Large Cap Avg |
|---|---|---|---|
| Analyst Rating | 2.24 | 2.40 | 2.41 |
| Analyst Count | 29 | 8 | 19 |
| Target Upside | +1.0% | +134.2% | +21.5% |
| P/E Ratio | 31.86 | 31.62 | 38.49 |
Revenue Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $14.53B | $14.76B | $15.24B | 16 |
| 2027-12-31 | $15.20B | $15.44B | $16.18B | 15 |
| 2028-03-31 | $3.77B | $3.85B | $3.95B | 4 |
| 2028-06-30 | $3.95B | $4.03B | $4.14B | 4 |
| 2028-09-30 | $4.03B | $4.11B | $4.23B | 4 |
| 2028-12-31 | $4.02B | $4.10B | $4.21B | 4 |
| 2029-03-31 | $4.31B | $4.40B | $4.52B | 5 |
| 2029-06-30 | $4.50B | $4.59B | $4.72B | 5 |
| 2029-09-30 | $4.59B | $4.68B | $4.81B | 5 |
| 2029-12-31 | $4.55B | $4.64B | $4.77B | 5 |
| 2030-12-31 | $17.39B | $17.73B | $18.29B | 5 |
EPS Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $1.86 | $1.90 | $1.96 | 15 |
| 2027-12-31 | $2.01 | $2.15 | $2.27 | 15 |
| 2028-03-31 | $0.52 | $0.54 | $0.56 | 7 |
| 2028-06-30 | $0.62 | $0.64 | $0.66 | 6 |
| 2028-09-30 | $0.63 | $0.65 | $0.67 | 6 |
| 2028-12-31 | $0.60 | $0.62 | $0.64 | 7 |
| 2029-03-31 | $0.63 | $0.65 | $0.67 | 10 |
| 2029-06-30 | $0.73 | $0.75 | $0.78 | 9 |
| 2029-09-30 | $0.77 | $0.79 | $0.82 | 9 |
| 2029-12-31 | $0.72 | $0.74 | $0.77 | 10 |
| 2030-12-31 | $2.71 | $2.78 | $2.90 | 2 |
Frequently Asked Questions
What is the analyst consensus for CSX?
The consensus among 29 analysts covering CSX Corporation (CSX) is Buy with an average price target of $51.06.
What is the highest price target for CSX?
The highest price target for CSX is $105.00, set by Chris Caso at Wolfe Research on 2024-01-22.
What is the lowest price target for CSX?
The lowest price target for CSX is $25.00, set by Ravi Shanker at Morgan Stanley on 2022-01-21.
How many analysts cover CSX?
29 analysts have issued ratings for CSX Corporation in the past 12 months.
Is CSX a buy or sell right now?
Based on 29 analyst ratings, CSX has a consensus rating of Buy (2.24/5) with a +1.0% upside to the consensus target of $51.06.
What are the earnings estimates for CSX?
Analysts estimate CSX will report EPS of $1.90 for the period ending 2026-12-31, with revenue estimated at $14.76B.
Related Stock Forecasts
Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.